AstraZeneca
Last updated: . For recent data, use our API.
Overview
(NYSE: AZN · $171.49 ▼ 0.6%) We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com.
Community Guidelines: bit.ly/2MgAcio
Private funding before listing
Disclosed funding: $43.6M across 3 rounds. Latest: POST IPO DEBT, 1 Aug 2026.
1 round has an undisclosed amount, not included in the total.
| Date | Type | Amount |
|---|---|---|
| 1 Aug 2026 | POST IPO DEBT | Not disclosed |
Office locations
Similar companies
- PfizerPharmaceutical Manufacturing · New York
- NovartisPharmaceutical Manufacturing · Basel, Baselstadt
- SanofiPharmaceutical Manufacturing · Paris, France
- GSKPharmaceutical Manufacturing · London, England
- RocheBiotechnology Research
- Eli Lilly and CompanyPharmaceutical Manufacturing · Indianapolis, Indiana
- Johnson & JohnsonHospitals and Health Care · New Brunswick, NJ
- Novo NordiskPharmaceutical Manufacturing
- BayerChemical Manufacturing · Leverkusen, North Rhine-Westphalia
- AbbViePharmaceutical Manufacturing · North Chicago, Illinois
Latest videos from AstraZeneca on YouTube
Rare Connections in HPP
T-cell Engagers Explained: Redirecting T-cells Against Cancer
Haematology Cell Therapy Explained: Harnessing the Immune System to Target Blood Cancer
Immunology R&D: Unlocking the science
Recent posts from the AstraZeneca blog
- Medical evidence generation involves many steps, teams, tools and data.
When they're disconnected, context can be lost and work repeated. Velocia is an ecosystem of purpose-built agentic AI agents designed to support tasks across the evidence generation journey.
- Cancer clinical trials are an important part of cancer research.
These carefully monitored studies evaluate the safety and effectiveness of treatments for people living with cancer. Including diverse communities in cancer clinical trials can help researchers better understand how treatments may work across different groups of people – potentially improving cancer care for not only those participating, but others as well.